Evidence map›Paper›PMID 25938566›Full record

ArticlePloS one2015

The Reg3α (HIP/PAP) Lectin Suppresses Extracellular Oxidative Stress in a Murine Model of Acute Liver Failure.

Nicolas Moniaux, Marion Darnaud, Kévin Garbin, Alexandre Dos Santos, Catherine Guettier, Didier Samuel, Gilles Amouyal, Paul Amouyal, Christian Bréchot, Jamila Faivre

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Nicolas MoniauxINSERM, U1193, Centre Hépatobiliaire, Villejuif, F-94800, France; Université Paris-Sud, Faculté de Médecine, Villejuif, F-94800, France.
Marion DarnaudINSERM, U1193, Centre Hépatobiliaire, Villejuif, F-94800, France; Université Paris-Sud, Faculté de Médecine, Villejuif, F-94800, France.
Kévin GarbinINSERM, U1193, Centre Hépatobiliaire, Villejuif, F-94800, France; Université Paris-Sud, Faculté de Médecine, Villejuif, F-94800, France.
Alexandre Dos SantosINSERM, U1193, Centre Hépatobiliaire, Villejuif, F-94800, France; Université Paris-Sud, Faculté de Médecine, Villejuif, F-94800, France.
Catherine GuettierINSERM, U1193, Centre Hépatobiliaire, Villejuif, F-94800, France; Université Paris-Sud, Faculté de Médecine, Villejuif, F-94800, France; Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Universitaire Paul Brousse, Villejuif, F-94800, France.
Didier SamuelINSERM, U1193, Centre Hépatobiliaire, Villejuif, F-94800, France; Université Paris-Sud, Faculté de Médecine, Villejuif, F-94800, France; Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Universitaire Paul Brousse, Villejuif, F-94800, France.
Gilles AmouyalAlfact Innovation, Paris, France.
Paul AmouyalAlfact Innovation, Paris, France.
Christian BréchotINSERM, U1193, Centre Hépatobiliaire, Villejuif, F-94800, France; Université Paris-Sud, Faculté de Médecine, Villejuif, F-94800, France.
Jamila FaivreINSERM, U1193, Centre Hépatobiliaire, Villejuif, F-94800, France; Université Paris-Sud, Faculté de Médecine, Villejuif, F-94800, France; Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Universitaire Paul Brousse, Villejuif, F-94800, France.
Inserm · FRAlfact Innovation (France) · FRUniversité Paris-Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsAcute liver failure (ALF) is a rapidly progressive heterogeneous illness with high mortality rate and no widely accessible cure. A promising drug candidate according to previous preclinical studies is the Reg3α (or HIP/PAP) lectin, which alleviates ALF through its free-radical scavenging activity. Here we study the therapeutic targets of Reg3α in order to gain information on the nature of the oxidative stress associated with ALF.

methodsPrimary hepatocytes stressed with the reactive oxygen species (ROS) inducers TNFα and H2O2 were incubated with a recombinant Reg3α protein. ALF was induced in C57BL/6J mice by an anti-CD95 antibody. Livers and primary hepatocytes were harvested for deoxycholate separation of cellular and extracellular fractions, immunostaining, immunoprecipitation and malondialdehyde assays. Fibrin deposition was studied by immunofluorescence in frozen liver explants from patients with ALF.

resultsFibrin deposition occurs during experimental and clinical acute liver injuries. Reg3α bound the resulting transient fibrin network, accumulated in the inflammatory extracellular matrix (ECM), greatly reduced extracellular ROS levels, and improved cell viability. Hepatocyte treatment with ligands of death receptors, e.g. TNFα and Fas, resulted in a twofold increase of malondialdehyde (MDA) level in the deoxycholate-insoluble fractions. Reg3α treatment maintained MDA at a level similar to control cells and thereby increased hepatocyte survival by 35%. No antioxidant effect of Reg3α was noted in the deoxycholate-soluble fractions. Preventing fibrin network formation with heparin suppressed the prosurvival effect of Reg3α.

conclusionsReg3α is an ECM-targeted ROS scavenger that binds the fibrin scaffold resulting from hepatocyte death during ALF. ECM alteration is an important pathogenic factor of ALF and a relevant target for pharmacotherapy.

Indexed as

Oxidative StressAdultAgedAnimalsAntigens, NeoplasmBiomarkers, TumorCells, CulturedDisease Models, AnimalExtracellular MatrixExtracellular Spacefas ReceptorFemaleFibrinHepatocytesHumansLectins, C-TypeAntigens, NeoplasmBiomarkers, Tumorfas ReceptorFibrinLectins, C-TypePancreatitis-Associated ProteinsREG3A protein, human

Identifiers

PMID25938566
PMCPMC4418718
OpenAlexW259293870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.